Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

• Status: Not yet recruiting
• Trial end date: 2024-01-30
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the value of blood eosinophils, FeNO and total IgE in predicting the response to inhaled corticosteroid in patients with chronic cough.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University
• Collaborators: Beijing Chao Yang Hospital; China-Japan Friendship Hospital; Chongqing Songshan Hospital; First Hospital of China Medical University; Guangdong Provincial Hospital of Traditional Chinese Medicine; Henan Provincial People's Hospital; Huizhou Third People's Hospital; Inner Mongolia People's Hospital; Nanfang Hospital of Southern Medical University; Ruijin Hospital; Second Hospital of Jilin University; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shenzhen People's Hospital; SSL Central Hospital of Dongguan City; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine; The First Affiliated Hospital of Shanxi Medical University; The First People's Hospital of Yunnan; Tongji Hospital; Zunyi Medical College
• Treatments: Beclomethasone; Formoterol Fumarate

Criteria

Inclusion Criteria:

1. Age: 18-70 years;

2. Coughing lasting ≥ 8 weeks；

3. No abnormality in chest imaging in the past 3 months (or there is abnormality but the investigator judges it not the cause of chronic cough)；

4. FEV1% pred>70%；FEV1/FVC>70%；

5. VAS≥30 in the past 48 hours;

6. Non-smokers or patients smoked less than 10 pack-years;

7. Candidates voluntarily participate in and abide by the relevant regulations of the study, can cooperate with corresponding inspections, follow the follow-up plan, and voluntarily sign written informed consent.

Exclusion Criteria:

1. Patients received inhaled or oral corticosteroids or leukotriene receptor antagonist in previous 4 weeks;

2. Patients with history of upper respiratory tract infection in the past 8 weeks;

3. Patients taking angiotensin-converting enzyme inhibitors in previous 8 weeks;

4. Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study;

5. Combined with a definite history of pulmonary diseases such as bronchiectasis, pulmonary interstitial disease, and pulmonary hypertension. Combined with other serious diseases (such as cardiovascular system diseases, metabolic system diseases, immune system diseases, nervous system diseases, etc.) that may affect the normal process of this study;

6. Participating in other drug clinical trial projects.